Isotechnika updates investors on planned merger with Aurinia

Tweet Isotechnika Pharma (TSX:ISA) and closely-held Aurinia Pharmaceuticals have updated investors on their proposed merger to create a global nephrology company. The companies have now executed a definitive tripartite agreement with ILJIN Life Science. Subject to the successful completion of the proposed merger, the combined company will re-acquire full rights to voclosporin for autoimmune indications, [...]

Glickman swinging for the fence again in Isotechnika merger

Tweet Richard Glickman is poised to hit another home run with the proposed merger of his closely-held Aurinia Pharmaceuticals and Isotechnika Pharma (TSX:ISA) to create a global nephrology leader. Dr. Glickman has a decades-long track record of successfully developing and selling pharmaceutical and biopharmaceutical companies. For example, in 2001, he co-founded Aspreva Pharmaceuticals which went [...]

Isotechnika merger with Aurinia to create nephrology leader

Tweet Isotechnika Pharma (TSX:ISA) and closely-held Aurinia Pharmaceuticals have signed a binding term sheet to merge and create a premier clinical-stage pharmaceutical company focused on the global nephrology market. Aurinia is a spin-out from Vifor Pharma, the pharmaceutical arm of Swiss-based Galenica Group. Aurinia’s current leadership team is comprised primarily of former senior managers, directors [...]

ILJIN withdraws damage claims against Isotechnika

Tweet Isotechnika Pharma (TSX:ISA) announced that ILJIN Life Sciences of South Korea has formally notified Isotechnika and the arbitral tribunal that it has withdrawn all claims for damages in the parties’ pending arbitration arising from a development, distribution and license agreement. As previously reported, the agreement was declared to be in “full force and effect” [...]

Isotechnika’s NICAMs effective against Hepatitis C virus

Tweet Isotechnika Pharma (TSX:ISA) has announced positive anti-hepatitis C virus (HCV) results from the second round of in vitro testing of its cyclophilin antagonist molecules (NICAMs) carried out by the NIH’s National Institute of Allergy and Infectious Diseases. Several NICAM compounds were tested for cross genotype activity using quantitative polymerase chain reaction in HCV replicons, [...]

Isotechnika receives partial award in ICC arbitration

Tweet Isotechnika Pharma (TSX:ISA) has received a partial award from the International Chamber of Commerce Court of Arbitration regarding its right to terminate a development, distribution and license (DDL) agreement with ILJIN Life Sciences of South Korea. The partial award provides that the DDL has not been terminated and the company’s contractual relationship with ILJIN [...]

FDA clears Isotechnika for Phase 3 voclosporin trial

Tweet Isotechnika Pharma (TSX:ISA) has received permission from the FDA to commence the first of two planned Phase 3 kidney transplant trials for its lead product candidate, voclosporin, under a special protocol assessment (SPA) from the FDA. The SPA was received after the FDA reviewed Isotechnika’s Phase 2b data and evaluated the proposed Phase 3 [...]

Isotechnika highlights upcoming milestones in Q3 report

Tweet Isotechnika Pharma (TSX:ISA) expects a decision shortly from the International Chamber of Commerce (ICC) Court of Arbitration on its right to terminate a development, distribution and license agreement with ILJIN Life Science Co. Isotechnika made the disclosure in its third quarter report. It terminated the accord with ILJIN last January. In addition, Isotechnika partner [...]

Isotechnika’s NICAMs demonstrate anti-viral activity

Tweet Isotechnika Pharma (TSX: ISA) announced positive results from the first round of screening of its portfolio of cyclophilin antagonist molecules (NICAMs) through the contract testing laboratories of the National Institute of Allergy and Infectious Disease, which is part of the NIH. NICAMs are an emerging novel class of multifunctional drugs showing promise as antiviral, [...]

Isotechnika partner cleared for Phase 3 trial in China

Tweet Isotechnika Pharma (TSX:ISA) partner 3SBio (NASDAQ:SSRX) has received approval from the China’s State Food and Drug Administration to conduct a multi-center, Phase 3 clinical trial of voclosporin. According to the approved protocol, the randomized, multi-center, concentration-controlled and comparison study in kidney transplant patients is expected to begin enrolment in the third quarter of 2012. [...]

Next Page »